Stopping Ozempic or Wegovy Because It's Too Expensive: How to Do It as Safely as Possible

If the monthly cost has reached the point where you cannot keep paying for your GLP-1, you are in the most common situation there is for stopping one. Cost is the leading reason people come off these drugs, and being forced off by price is not the same as deciding you are done. It is involuntary, it is frustrating, and it is not a failure of willpower. This page is here to help you handle it well.

A first, important reframe: coming off a GLP-1 is not an acute medical emergency the way stopping some drugs can be. There is no dangerous withdrawal syndrome. What changes is that appetite returns as the medication clears, and weight tends to drift back — which is exactly why doing this deliberately, rather than by running out of vials, is worth the effort. (One exception: if you take a GLP-1 for type 2 diabetes, stopping affects your blood-sugar control and is a conversation to have with your prescriber before you stop, not after.)

We are an independent publication, not a prescriber or pharmacy. Nothing here is medical advice. Any change to your dose or to whether you stay on therapy is a decision for you and a licensed clinician.

First: are you sure you have to stop?

Many people conclude they are out of options when they are one phone call away from a cheaper route they did not know existed. Before you accept being forced off, work through these:

• Appeal a prior-authorization denial. If insurance refused to cover your GLP-1, denials are frequently overturned on appeal, especially with a documented comorbidity. Our GLP-1 prior-authorization appeal guide walks through how.
• Use the manufacturer savings cards. Commercially insured patients can sometimes pay far less with a copay card. See the GLP-1 savings card guide.
• Re-check cash-pay — it has come down. Manufacturer pharmacies narrowed the gap that drove people to compounding: Wegovy through NovoCare runs $349/month(as of May 2026) a month and Zepbound vials through LillyDirect start at $299/month. That may still be a stretch, but it is often less than people assume.
• Consider a cheaper or oral alternative. An older GLP-1 or an oral option may cost less than what you are on. We lay out the lower-cost routes in cheaper GLP-1 alternatives.

If your access ended because a compounded supply was discontinued rather than because of insurance, our guide to your choices when a compounded GLP-1 is discontinued lays every path side by side. The point of this section is simple: rule out the affordable routes before you treat stopping as inevitable.

The “make it last” conversation — with your prescriber

If full-price, full-dose therapy is genuinely out of reach, there is a question worth raising with your prescriber: could a lower maintenance dose or a longer interval between doses keep you on treatment at a price you can manage? Some people hold much of their progress on less drug than they used to reach it, and our GLP-1 maintenance dose and GLP-1 drug holidays explainers cover what that can look like.

The non-negotiable caveat: this is a clinical decision, not a do-it-yourself one. Skipping, splitting, or stretching doses on your own to save money can mean losing appetite or blood-sugar control without the savings being worth it — and with a self-drawn dose it is easy to get the amount wrong. Ask the question directly and let a clinician answer it for your situation.

If you genuinely have to stop: do it on purpose

If there is no affordable way to continue, the single most useful thing you can do is stop deliberately instead of simply running out. Coming off by attrition — using your last vial and then nothing — gives you no plan for the appetite that returns. A planned wind-down does.

• Talk to your prescriber about a taper. Where appropriate, a gradual step-down is gentler than a hard stop, and some people continue to do well through a slow taper. Whether and how to taper is a clinical call; our tapering off GLP-1 drugs guide covers what published protocols and obesity-medicine practice actually do.
• Know what the stop itself feels like. Appetite, food thoughts, and earlier hunger return over the weeks after your last dose. The drug-specific picture is in stopping Wegovy: what happens and stopping Zepbound: what happens.
• Time it around your supply, not against it. If you have a few doses left, that is the window to plan the taper and shore up your habits — not a buffer to ignore until it is gone.

What to honestly expect

It helps to go in with realistic numbers rather than fear. After stopping, the appetite-suppressing effect fades and the body defends its prior weight: ghrelin rises, fullness comes later, and food regains its pull. On average, people regain a majority of the weight they lost within roughly a year — but, importantly, they still keep off about a quarter of the original loss, and many hold considerably more (University of Cambridge analysis; see also Scientific American).

Two things matter about those numbers. First, regain is physiology, not a moral verdict — it is the hormonal state the drug was holding back returning to baseline. Second, the average hides a wide range: a meaningful share of people keep much more off, and the difference is shaped by what you do next. Our weight regain after GLP-1s page has the full trial detail if you want it.

Holding on to what you can

You cannot replicate a GLP-1 with willpower, but the habits you built while appetite was quiet are real assets, and a few things genuinely help blunt regain:

• Protect protein. Adequate protein supports the lean mass that keeps your metabolic rate up; see GLP-1 protein requirements.
• Lift, don’t just cut. Resistance training defends muscle against the regain process and is one of the better-supported maintenance levers.
• Keep the structure. The smaller portions, the higher-fibre, higher-protein meals, the routine — these can persist after the drug and are worth holding onto deliberately rather than letting them slide with returning appetite.
• Watch the trend, not the day. Weighing the weekly trend rather than reacting to daily noise helps you catch drift early, while it is still small.

None of this stops regain entirely, and it is not meant to. The goal is to keep as much of your progress as the situation allows, without pretending the drug was optional.

The temptation to avoid

When cost is the thing forcing you off, the cheap peptides advertised online — “research-grade,” “not for human consumption” — can look like a lifeline. They are not. They are a fundamentally different and more dangerous risk category than a pharmacy-made medicine, with no verified identity, purity, or sterility, and no one accountable if they harm you. We explain exactly why in is research-grade semaglutide safe?. If money is the problem, the legitimate routes at the top of this page are a far safer place to spend your effort.

A last word

Being priced out of a treatment that was working is genuinely hard, and the regain that can follow is not evidence that you failed or that the drug was a crutch. Obesity is a chronic condition, and stopping for cost is rarely permanent — insurance changes, prices move, new options arrive. Manage this stretch as well as you can, keep a record of your dose and tolerance so restarting later is easy, and treat this as a pause you are handling, not a verdict.

This article is educational and informational only. It is not medical advice. Decisions about stopping, tapering, changing your dose, or staying on therapy — especially if you take a GLP-1 for diabetes — belong to you and a licensed healthcare professional. If you are in crisis or experiencing a medical emergency, contact your local emergency services.